Atogepant (Aquipta®)

Clinical Indication

Prophylaxis of migraine

Comments

For preventing migraine in adults who have at least 4 migraine days per month and if at least 3 different classes of preventative medicines have not worked, or are not tolerated, or are unsuitable due to safety concerns. See NICE TA973 for full details.

To be prescribed in line with the LLR Migraine pathway

Date of classification

July 2024

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.